{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T02:13:41Z","timestamp":1778638421026,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Tampere University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-026-04854-0","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T05:36:31Z","timestamp":1775108191000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patterns of levetiracetam and lacosamide use for treatment of status epilepticus with respect to clinical features and prior antiseizure medications"],"prefix":"10.1186","volume":"26","author":[{"given":"Teemu","family":"P\u00f6yt\u00e4kangas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pabitra","family":"Basnyat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jukka","family":"Saarinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sirpa","family":"Rainesalo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jukka","family":"Peltola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"4854_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1474-4422(24)00430-7","volume":"24","author":"JV Gettings","year":"2025","unstructured":"Gettings JV, Mohammad Alizadeh Chafjiri F, Patel AA, Shorvon S, Goodkin HP, Loddenkemper T. Diagnosis and management of status epilepticus: improving the status quo. Lancet Neurol. 2025;24:65\u201376. https:\/\/doi.org\/10.1016\/S1474-4422(24)00430-7.","journal-title":"Lancet Neurol"},{"key":"4854_CR2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.5698\/1535-7597-16.1.48","volume":"16","author":"T Glauser","year":"2016","unstructured":"Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016;16:48\u201361. https:\/\/doi.org\/10.5698\/1535-7597-16.1.48.","journal-title":"Epilepsy Curr"},{"key":"4854_CR3","first-page":"1385","volume":"132","author":"B K\u00e4lvi\u00e4inen Reetta","year":"2016","unstructured":"K\u00e4lvi\u00e4inen Reetta B, Stepani J, Henna Ker\u00e4nen, Tapani K, Jouni S, Tapani, et al. Update on current care guideline: Status epilepticus. Duodecim. 2016;132:1385\u20136.","journal-title":"Duodecim"},{"key":"4854_CR4","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1468-1331.2009.02917.x","volume":"17","author":"H Meierkord","year":"2010","unstructured":"Meierkord H, Boon P, Engelsen B, G\u00f6cke K, Shorvon S, Tinuper P, et al. EFNS guideline on the management of status epilepticus in adults. Euro J Neurol. 2010;17:348\u201355. https:\/\/doi.org\/10.1111\/j.1468-1331.2009.02917.x.","journal-title":"Euro J Neurol"},{"key":"4854_CR5","doi-asserted-by":"publisher","first-page":"117542","DOI":"10.1016\/j.jns.2021.117542","volume":"427","author":"JJ Sairanen","year":"2021","unstructured":"Sairanen JJ, Kantanen A-M, Hypp\u00f6l\u00e4 HT, K\u00e4lvi\u00e4inen RK. Status epilepticus: Practice variation and adherence to treatment guideline in a large community hospital. J Neurol Sci. 2021;427:117542. https:\/\/doi.org\/10.1016\/j.jns.2021.117542.","journal-title":"J Neurol Sci"},{"key":"4854_CR6","doi-asserted-by":"publisher","first-page":"107218","DOI":"10.1016\/j.eplepsyres.2023.107218","volume":"196","author":"T P\u00f6yt\u00e4kangas","year":"2023","unstructured":"P\u00f6yt\u00e4kangas T, Saarinen JT, Basnyat P, Rainesalo S, Peltola J. Indications for the use of intravenous second-line antiseizure medications in an emergency room setting. Epilepsy Res. 2023;196:107218. https:\/\/doi.org\/10.1016\/j.eplepsyres.2023.107218.","journal-title":"Epilepsy Res"},{"key":"4854_CR7","doi-asserted-by":"publisher","first-page":"1685993","DOI":"10.3389\/fneur.2025.1685993","volume":"16","author":"L M\u00f6ller","year":"2025","unstructured":"M\u00f6ller L, Fisch U, Habermehl L, J\u00fcnemann C. Treating status epilepticus in clinical practice\u2014a multi-national survey in Germany, Austria, and Switzerland. Front Neurol. 2025;16:1685993. https:\/\/doi.org\/10.3389\/fneur.2025.1685993.","journal-title":"Front Neurol"},{"key":"4854_CR8","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/epi.13716","volume":"58","author":"A Strzelczyk","year":"2017","unstructured":"Strzelczyk A, Z\u00f6llner JP, Willems LM, Jost J, Paule E, Schubert-Bast S, et al. Lacosamide in status epilepticus: Systematic review of current evidence. Epilepsia. 2017;58:933\u201350. https:\/\/doi.org\/10.1111\/epi.13716.","journal-title":"Epilepsia"},{"key":"4854_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.seizure.2016.01.008","volume":"39","author":"N Lang","year":"2016","unstructured":"Lang N, Lange M, Schmitt FC, B\u00f6s M, Weber Y, Evers S, et al. Intravenous lacosamide in clinical practice\u2013Results from an independent registry. Seizure. 2016;39:5\u20139. https:\/\/doi.org\/10.1016\/j.seizure.2016.01.008.","journal-title":"Seizure"},{"key":"4854_CR10","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/S0140-6736(20)30611-5","volume":"395","author":"JM Chamberlain","year":"2020","unstructured":"Chamberlain JM, Kapur J, Shinnar S, Elm J, Holsti M, Babcock L, et al. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. Lancet. 2020;395:1217\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(20)30611-5.","journal-title":"Lancet"},{"key":"4854_CR11","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jocn.2014.12.013","volume":"22","author":"S Chakravarthi","year":"2015","unstructured":"Chakravarthi S, Goyal MK, Modi M, Bhalla A, Singh P. Levetiracetam versus phenytoin in management of status epilepticus. J Clin Neurosci. 2015;22:959\u201363. https:\/\/doi.org\/10.1016\/j.jocn.2014.12.013.","journal-title":"J Clin Neurosci"},{"key":"4854_CR12","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.eplepsyres.2015.04.013","volume":"114","author":"RC Mundlamuri","year":"2015","unstructured":"Mundlamuri RC, Sinha S, Subbakrishna DK, Prathyusha PV, Nagappa M, Bindu PS, et al. Management of generalised convulsive status epilepticus (SE): A prospective randomised controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam \u2013 Pilot study. Epilepsy Res. 2015;114:52\u20138. https:\/\/doi.org\/10.1016\/j.eplepsyres.2015.04.013.","journal-title":"Epilepsy Res"},{"key":"4854_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.seizure.2019.01.015","volume":"65","author":"D Nene","year":"2019","unstructured":"Nene D, Mundlamuri RC, Satishchandra P, Prathyusha PV, Nagappa M, Bindu PS, et al. Comparing the efficacy of sodium valproate and levetiracetam following initial lorazepam in elderly patients with generalized convulsive status epilepticus (GCSE): A prospective randomized controlled pilot study. Seizure. 2019;65:111\u20137. https:\/\/doi.org\/10.1016\/j.seizure.2019.01.015.","journal-title":"Seizure"},{"key":"4854_CR14","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1905795","volume":"381","author":"J Kapur","year":"2019","unstructured":"Kapur J, Elm J, Chamberlain JM, Barsan W, Cloyd J, Lowenstein D, et al. Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. N Engl J Med. 2019;381:2103\u201313. https:\/\/doi.org\/10.1056\/NEJMoa1905795.","journal-title":"N Engl J Med"},{"key":"4854_CR15","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40261-015-0295-5","volume":"35","author":"EY Moreno Morales","year":"2015","unstructured":"Moreno Morales EY, Fernandez Peleteiro M, Bondy Pe\u00f1a EC, Dom\u00ednguez Lorenzo JM, Pardellas Santiago E, Fern\u00e1ndez A. Observational study of intravenous lacosamide in patients with convulsive versus non-convulsive status epilepticus. Clin Drug Investig. 2015;35:463\u20139. https:\/\/doi.org\/10.1007\/s40261-015-0295-5.","journal-title":"Clin Drug Investig"},{"key":"4854_CR16","doi-asserted-by":"publisher","first-page":"e0238201","DOI":"10.1371\/journal.pone.0238201","volume":"15","author":"Y-J Tseng","year":"2020","unstructured":"Tseng Y-J, Huang S-Y, Kuo C-H, Wang C-Y, Wang K-C, Wu C-C. Safety range of free valproic acid serum concentration in adult patients. PLoS ONE. 2020;15:e0238201. https:\/\/doi.org\/10.1371\/journal.pone.0238201.","journal-title":"PLoS ONE"},{"key":"4854_CR17","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1586\/14737175.2015.1074523","volume":"15","author":"M Pop\u0142awska","year":"2015","unstructured":"Pop\u0142awska M, Borowicz KK, Czuczwar SJ. The safety and efficacy of fosphenytoin for the treatment of status epilepticus. Expert Rev Neurother. 2015;15:983\u201392. https:\/\/doi.org\/10.1586\/14737175.2015.1074523.","journal-title":"Expert Rev Neurother"},{"key":"4854_CR18","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/phar.2687","volume":"42","author":"A Jense","year":"2022","unstructured":"Jense A, Douville A, Weiss A. The safety of rapid infusion levetiracetam: A systematic review. Pharmacotherapy. 2022;42:495\u2013503. https:\/\/doi.org\/10.1002\/phar.2687.","journal-title":"Pharmacotherapy"},{"key":"4854_CR19","doi-asserted-by":"publisher","unstructured":"Samsonsen C, Reimers A, Br\u00e5then G, Helde G, Brodtkorb E. Nonadherence to treatment causing acute hospitalizations in people with epilepsy: An observational, prospective study. Epilepsia. 2014;55. https:\/\/doi.org\/10.1111\/epi.12801.","DOI":"10.1111\/epi.12801"},{"key":"4854_CR20","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s40265-021-01502-4","volume":"81","author":"P Bravo","year":"2021","unstructured":"Bravo P, Vaddiparti A, Hirsch LJ. Pharmacotherapy for Nonconvulsive Seizures and Nonconvulsive Status Epilepticus. Drugs. 2021;81:749\u201370. https:\/\/doi.org\/10.1007\/s40265-021-01502-4.","journal-title":"Drugs"},{"key":"4854_CR21","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.neulet.2016.12.044","volume":"667","author":"MC Walker","year":"2018","unstructured":"Walker MC. Pathophysiology of status epilepticus. Neurosci Lett. 2018;667:84\u201391. https:\/\/doi.org\/10.1016\/j.neulet.2016.12.044.","journal-title":"Neurosci Lett"},{"key":"4854_CR22","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.seizure.2020.08.021","volume":"81","author":"M Sadeghi","year":"2020","unstructured":"Sadeghi M, Eshraghi M, Akers KG, Hadidchi S, Kakara M, Nasseri M, et al. Outcomes of status epilepticus and their predictors in the elderly\u2014A systematic review. Seizure. 2020;81:210\u201321. https:\/\/doi.org\/10.1016\/j.seizure.2020.08.021.","journal-title":"Seizure"},{"key":"4854_CR23","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/ane.13363","volume":"143","author":"\u00c1 Guti\u00e9rrez-Viedma","year":"2021","unstructured":"Guti\u00e9rrez-Viedma \u00c1, Parejo-Carbonell B, Romeral-Jim\u00e9nez M, Sanz-Graciani I, Serrano-Garc\u00eda I, Cuadrado M-L, et al. Therapy delay in status epilepticus extends its duration and worsens its prognosis. Acta Neurol Scand. 2021;143:281\u20139. https:\/\/doi.org\/10.1111\/ane.13363.","journal-title":"Acta Neurol Scand"},{"key":"4854_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.seizure.2017.12.007","volume":"55","author":"L K\u00e4mppi","year":"2018","unstructured":"K\u00e4mppi L, Mustonen H, Kotisaari K, Soinila S. The essence of the first 2.5\u00a0h in the treatment of generalized convulsive status epilepticus. Seizure. 2018;55:9\u201316. https:\/\/doi.org\/10.1016\/j.seizure.2017.12.007.","journal-title":"Seizure"},{"key":"4854_CR25","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1111\/epi.16382","volume":"60","author":"A Fechner","year":"2019","unstructured":"Fechner A, Hubert K, Jahnke K, Knake S, Konczalla J, Menzler K, et al. Treatment of refractory and superrefractory status epilepticus with topiramate: A cohort study of 106 patients and a review of the literature. Epilepsia. 2019;60:2448\u201358. https:\/\/doi.org\/10.1111\/epi.16382.","journal-title":"Epilepsia"},{"key":"4854_CR26","doi-asserted-by":"publisher","first-page":"107507","DOI":"10.1016\/j.eplepsyres.2025.107507","volume":"210","author":"T P\u00f6yt\u00e4kangas","year":"2025","unstructured":"P\u00f6yt\u00e4kangas T, Basnyat P, Rainesalo S, Peltola J, Saarinen JT. Use of benzodiazepines in patients with status epilepticus requiring second-line antiseizure medication treatment. Epilepsy Res. 2025;210:107507. https:\/\/doi.org\/10.1016\/j.eplepsyres.2025.107507.","journal-title":"Epilepsy Res"},{"key":"4854_CR27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1865-1380-6-6","volume":"6","author":"J Hillman","year":"2013","unstructured":"Hillman J, Lehtim\u00e4ki K, Peltola J, Liimatainen S. Clinical significance of treatment delay in status epilepticus. Int J Emerg Med. 2013;6:6. https:\/\/doi.org\/10.1186\/1865-1380-6-6.","journal-title":"Int J Emerg Med"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-04854-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04854-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04854-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T02:03:57Z","timestamp":1778637837000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-04854-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4854"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-04854-0","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As the study involved no contact with patients, ethical committee approval and informed consent were not required under the Finnish Law on Research. In accordance with Finnish guidelines, the study was approved by the Head of the Tampere University Science Centre and followed the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"T.P, P.B, J.S, and S.R report no conflicts of interest. J.P has participated in clinical trials for Bial, Biohaven, Eisai, and UCB; received research grants from Angelini Pharma, Jazz Pharma, Eisai, Medtronic, UCB, and LivaNova; received speaker honoraria from Angelini Pharma, Eisai, Jazz Pharma, LivaNova, Medtronic, Orion Pharma, Takeda and UCB; received support for travel to congresses from LivaNova, Eisai, Medtronic, and UCB; and participated in advisory boards for Angelini Pharma, Eisai, Jazz Pharma, LivaNova, Medtronic, Novartis, Pfizer, and UCB.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"318"}}